23.27  1.74 (8.08%)		05-21 15:40
Open: 21.12 High: 23.29 Volume: 1,123,372		Pre. Close: 21.53 Low: 20.97 Market Cap: 2,225(M)

Short term
Mid term
Targets	6-month :	29.08	1-year :	33.96
Resists	First :	24.89	Second :	29.08
Pivot price	22.12
Supports	First :	21.53	Second :	19.45
MAs	MA(5) :	20.97	MA(20) :	22.42
	MA(100) :	22.35	MA(250) :	16.62
MACD	MACD :	-0.4	Signal :	-0.2
%K %D	K(14,3) :	41.9	D(3) :	21.2
RSI	RSI(14): 54.2
52-week	High :	27.64	Low :	7.96

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ IMNM ] has closed below upper band by 32.7%. Bollinger Bands are 11.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	21.71 - 21.85	21.85 - 21.98
Low:	19.52 - 19.69	19.69 - 19.84
Close:	21.25 - 21.54	21.54 - 21.8

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Thu, 21 May 2026
What Do Recent Insider Sales at Immunome (IMNM) Signal - Kavout

Thu, 21 May 2026
Immunome Inc stock (US45254C1062): biotech investor attention after oncology pipeline update - AD HOC NEWS

Tue, 19 May 2026
Insider Buying: Jean Bienaime Acquires 5,000 Shares of Immunome Inc (IMNM) - GuruFocus

Tue, 19 May 2026
Immunome director Bienaime buys $103,500 in company stock - Investing.com

Tue, 19 May 2026
Director Bienaime adds 5,000 Immunome (IMNM) shares in open-market buy - Stock Titan

Mon, 18 May 2026
What Offers Immunome (IMNM) a Compelling Investment Opportunity? - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	113 (M)
Held by Insiders	9.442e+007 (%)
Held by Institutions	6.3 (%)
Shares Short	18,950 (K)
Shares Short P.Month	0 (K)

EPS	-2.2635e+008
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-5 %
Return on Assets (ttm)	698.8 %
Return on Equity (ttm)	-29.8 %
Qtrly Rev. Growth	4.01e+006 %
Gross Profit (p.s.)	0
Sales Per Share	-23.66
EBITDA (p.s.)	-8.6217e+007
Qtrly Earnings Growth	-2.4 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-197 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.97
Price to Cash Flow	9.33

Dividend	0
Forward Dividend	1.866e+007
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.